Figure 7.

The unique T cell composition in PPSSC tumors results in enhanced efficacy of anti-LAG3 and anti-PD-1 immunotherapy

(A) T cells from KPPC and PPSSC tumors were classified into indicated subclusters: FoxP3⁺CD4⁺ regulatory T (Treg) cells, FoxP3⁻CD4⁺ effector T (Teff) cells, and CD8⁺ T cells, as shown in the UMAP plot.

(B) The expression profiles of signature genes of indicated T cell subclusters were depicted in the dot plot.

(C) The abundance (%) of indicated T cell subclusters from KPPC and PPSSC tumors was shown in the pie charts.

(D) The expression profile of Lag3 in KPPC and PPSSC tumors, as compared in the UMAP plot.

(E and F) Representative images of immunofluorescence staining for LAG3 (E), CD4 and FoxP3 (F), and nuclei/DAPI on tumor sections from KPPC mice (2.5-month-old) and stage-matched PPSSC mice (8-month-old) (n = 5/group). Quantitative results were shown with Student’s t test. Scale bar: 100 μm. ∗p < 0.05. See also Figures S10A and S10B.

(G) Representative images of CD8 immunohistochemistry staining on pancreatic tumor sections from KPPC mice (2.5-month-old) and stage-matched PPSSC mice (8-month-old) (n = 5/group). Quantitative results were shown with Student’s t test. Scale bar: 100 μm. ∗p < 0.05.

(H) Demonstration of endpoint pancreatic tumors from mice with indicated treatments.

(I and J) The endpoint tumor weight (I) and volume (J) of mice with indicated treatments (n = 5/group). Data were shown using one-way ANOVA with Tukey’s multiple comparison test. ∗p < 0.05, ∗∗p < 0.01. ns: not significant.

(K and L) Staining positivity quantification of Ki67 cells (K) and CD8⁺ cells (L) in orthotopic pancreatic tumors with indicated treatments. Data were shown using one-way ANOVA with Tukey’s multiple comparison test (n = 5/group). ∗p < 0.05, ∗∗∗∗p < 0.0001. ns: not significant. See also Figure S10D.